Belludi Ashwin, McFall Allison M, Solomon Sunil Suhas, Celentano David D, Mehta Shruti H, Srikrishnan A K, Kumar M Suresh, Solomon Suniti, Lucas Gregory M
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
PLoS One. 2021 Feb 25;16(2):e0247352. doi: 10.1371/journal.pone.0247352. eCollection 2021.
Pre-exposure prophylaxis (PrEP) is effective in reducing HIV transmission among key populations. In India, where PrEP is not currently part of the national HIV program, little is known about PrEP awareness, willingness to use PrEP, and barriers to uptake among people who inject drugs (PWID) and men who have sex with men (MSM).
We used respondent-driven sampling to accrue PWID and MSM in 22 sites from August 2016 to May 2017. Participants were asked about awareness of PrEP, willingness to use PrEP (following a brief description) and reasons why they might not be willing to use PrEP. Participants were also queried on preferences for PrEP delivery modality (oral vs. injectable). Multi-level logistic regression models were used to determine participant correlates of willingness to use PrEP. Estimates were weighted for the sampling method.
A total of 10,538 PWID and 8,621 MSM who self-reported being HIV-negative were included in the analysis. Only 6.1% (95% confidence interval [CI]: 5.9, 6.3) of PWID and 8.0% of MSM (95% CI: 7.7, 8.4) were aware of PrEP. However, willingness to use PrEP was substantially higher in both groups: 52.4% of PWID and 67.6% of MSM. Participants commonly cited a perceived low risk for acquiring HIV infection, being perceived by others as being HIV-positive, and side effects as reasons why they would be unwilling to use PrEP. Among PWID, sharing needles and hazardous alcohol use were associated with increased willingness to use PrEP. Among MSM, having a main male partner and injection drug use were associated with increased willingness to use PrEP. Preference for daily oral or monthly injectable PrEP was similar among MSM (39.6%% vs. 41.7%,), while PWID were more likely to prefer oral to injectable administration routes (56.3% vs. 31.1%).
As India plans to roll-out of PrEP in the public sector, our multi-city survey of PWID and MSM highlights the need for key population-focused education campaigns about PrEP and self-assessment of risk.
暴露前预防(PrEP)在减少重点人群中的艾滋病毒传播方面是有效的。在印度,PrEP目前并非国家艾滋病毒防治项目的一部分,对于注射吸毒者(PWID)和男男性行为者(MSM)对PrEP的知晓情况、使用PrEP的意愿以及接受PrEP的障碍知之甚少。
我们于2016年8月至2017年5月在22个地点采用应答驱动抽样法招募PWID和MSM。询问参与者对PrEP的知晓情况、使用PrEP的意愿(在简要介绍之后)以及他们可能不愿意使用PrEP的原因。还询问了参与者对PrEP给药方式(口服与注射)的偏好。使用多水平逻辑回归模型来确定与使用PrEP意愿相关的参与者因素。对抽样方法进行加权估计。
共有10538名自我报告为艾滋病毒阴性的PWID和8621名MSM纳入分析。只有6.1%(95%置信区间[CI]:5.9,6.3)的PWID和8.0%的MSM(95%CI:7.7,8.4)知晓PrEP。然而,两组中使用PrEP的意愿都显著更高:52.4%的PWID和67.6%的MSM。参与者普遍提到认为感染艾滋病毒的风险低、被他人视为艾滋病毒阳性以及副作用是他们不愿意使用PrEP的原因。在PWID中,共用针头和危险饮酒与使用PrEP的意愿增加有关。在MSM中,有主要男性伴侣和注射吸毒与使用PrEP的意愿增加有关。MSM中对每日口服或每月注射PrEP的偏好相似(39.6%对41.7%),而PWID更倾向于口服而非注射给药途径(56.3%对31.1%)。
随着印度计划在公共部门推出PrEP,我们对PWID和MSM的多城市调查强调了开展针对重点人群的PrEP教育活动以及风险自我评估的必要性。